Patents by Inventor Jieun A. Kim

Jieun A. Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
    Patent number: 7745151
    Abstract: Inhibitors of Nogo Receptor (NgR)-p75 binding are used to reduce NgR-p75 binding mediated axon growth inhibition. Mixtures of NgR and p75 are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to p75 and promoting axon regeneration.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: June 29, 2010
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Kevin C. Wang, Jieun A. Kim
  • Reducing myelin-mediated inhibition of axon regeneration
    Patent number: 7691590
    Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: April 6, 2010
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Kevin C. Wang, Vuk Koprivica, Jieun A. Kim
  • Reducing NgR-p75 mediated inhibition of axon regeneration
    Patent number: 7625709
    Abstract: Inhibitors of Nogo Receptor (NgR)-p75 binding are used to reduce NgR-p75 binding mediated axon growth inhibition. Mixtures of NgR and p75 are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to p75 and promoting axon regeneration.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: December 1, 2009
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Kevin C. Wang, Jieun A. Kim
  • Reducing Myelin-Mediated Inhibition of Axon Regeneration
    Publication number: 20080188411
    Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
    Type: Application
    Filed: December 18, 2007
    Publication date: August 7, 2008
    Inventors: Zhigang He, Kevin C. Wang, Vuk Koprivica, Jieun A. Kim
  • Reducing myelin-mediated inhibition of axon regeneration
    Patent number: 7309485
    Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: December 18, 2007
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Kevin C. Wang, Vuk Koprivica, Jieun A. Kim
  • Reducing NgR-p75 mediated inhibition of axon regeneration
    Publication number: 20040029169
    Abstract: Inhibitors of Nogo Receptor (NgR)-p75 binding are used to reduce NgR-p75 binding mediated axon growth inhibition. Mixtures of NgR and p75 are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to p75 and promoting axon regeneration.
    Type: Application
    Filed: August 2, 2002
    Publication date: February 12, 2004
    Applicant: Children's Medical Center Corporation
    Inventors: Zhigang He, Kevin C. Wang, Jieun A. Kim
  • Reducing myelin-mediated inhibition of axon regeneration
    Publication number: 20030113325
    Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
    Type: Application
    Filed: December 3, 2001
    Publication date: June 19, 2003
    Inventors: Zhigang He, Kevin C. Wang, Vuk Koprivica, Jieun A. Kim
  • Reducing myelin-mediated inhibition of axon regeneration
    Publication number: 20030113326
    Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
    Type: Application
    Filed: April 19, 2002
    Publication date: June 19, 2003
    Applicant: Children's Medical Center Corporation
    Inventors: Zhigang He, Kevin C. Wang, Vuk Koprivica, Jieun A. Kim